{"prompt": "['AVANOS', 'Genicular Nerve Lesion Study', 'Confidential', 'Protocol # 105-17-0001', '2', 'SYNOPSIS', 'Protocol Title:', '105-17-0001: A Prospective, Multi-center, Randomized, Clinical Trial Evaluating', 'the Safety and Effectiveness of Using COOLIEF TM Cooled Radiofrequency', 'Probe to Create Lesions of the Genicular Nerves and Comparing a Single', 'Injection of Hyaluronic Acid) in the Management of Knee Pain.', 'Test Article(s):', 'Treatment Group: COOLIEF TM Cooled Radiofrequency Probe (CRFA)', 'Control Group: Synvisc-One (HA)', 'Planned Number of', 'Up to 15 centers will be included in this study', 'Sites:', 'Planned Number of', 'Approximately 168', 'Subjects:', 'Study Design:', 'Prospective, Multicenter, Randomized, Comparison, Human, Interventional', 'Study Duration:', 'The primary study concludes at 12 months post randomized treatment,', 'however; an extension study will be offered to those who received COOLIEF*', 'as their originally randomized treatment to allow data collection through 24', 'months.', 'Treatment Group: Up to 24 months following index procedure', 'Control Group: Up to 13 months, depending upon receipt of Crossover', 'procedure.', 'Effectiveness', 'Numeric Rating Scale (NRS, Usual Level of Pain)', 'Endpoints:', 'Western Ontario & McMaster University Osteoarthritis Index (WOMAC)', 'EQ-5D-5L Health-Related Quality of Life Questionnaire', 'Global Perceived Effect Scale', 'Objectives:', 'To compare the effectiveness of CRFA to HA in the management of', 'moderate to severe knee pain in patients with radiologically-confirmeo', 'osteoarthritis to treatment with Viscosupplementation injection.', 'To confirm the safety of CRFA for creating radiofrequency lesions of the', 'genicular nerves for management of moderate to severe knee pain in', 'patients with radiologically-confirmeo osteoarthritis.', 'To capture the long term clinical outcomes (such as current level of pain,', 'function, and progression of disease through 24 months) for patients who', 'received CRFA as their initial treatment.', 'Selection Criteria:', 'Inclusion Criteria', '1. Age 21 years', '2.', 'Able to understand the informed consent form and provide written', 'informed consent and able to complete outcome measures', '3.', 'Chronic knee pain for longer than 6 months that interferes with', 'functional activities (for example, ambulation, prolonged standing, etc.)', '4.', 'Continued pain in the target knee despite at least 3 months of', 'conservative treatments, including activity modification, home exercise,', 'protective weight bearing, and/or analgesics (for example,', 'acetaminophen or non-steroidal anti-inflammatory drugs [NSAIDs])', 'Version #: 4.0', 'Page 4 of 62', 'Version Date: 28Mar19']['AVANOS', 'Genicular Nerve Lesion Study', 'Confidential', 'Protocol # 105-17-0001', '5.', 'Positive response (defined as a decrease in numeric pain scores of at', 'least 50%) to a single genicular nerve block of the index knee', '6.', 'Pain on NRS 6 on an 11-point scale for the index knee', '7. Radiologic confirmation of arthritis (x-ray/MRI/CT) of OA grade of 2', '(mild), 3 (moderate) or 4 (severe) noted within 6 months for the index', 'knee', '8. An intra-articular hyaluronic acid injection is indicated as an appropriate', 'treatment option', '9.', 'WOMAC Knee Score group at baseline of Score of 2 (0 to 4 scale) on', 'WOMAC question 1 (Pain) and a mean score of 1.5 on all five', 'questions of the WOMAC pain subscale.', '10. Analgesics including membrane stabilizers such as', 'Neurontin/gabapentin and antidepressants for pain such as Cymbalta', 'duloxetine must be clinically stable (defined as stable dosage for 6', 'weeks prior to the screening visit) and shall not change during the', 'course of the study without approval of the investigator', '11. Agree to see one physician (study physician) for knee pain during the', 'study period', '12. Willing to utilize double barrier contraceptive method if of child bearing', 'potential', '13. Willing to delay any surgical intervention for the index knee for the', 'period of the study follow up', '14. Willingness to provide informed consent and to comply with the', 'requirements of this protocol for the full duration of the study', 'Exclusion Criteria', '1. Evidence of inflammatory arthritis (for example, rheumatoid arthritis) or', 'other systemic inflammatory condition (for example, gout, fibromyalgia)', 'that could cause knee pain', '2. Evidence of neuropathic pain affecting the index knee', '3. Previous or pending lower limb amputation', '4.', 'Intra-articular steroid injection into the index knee within 90 days from', 'randomization', '5. Hyaluronic acid injection, platelet rich plasma (PRP), stem cell, or', 'arthroscopic debridement/lavage injection into the index knee within', '180 days from randomization', '6. Prior radiofrequency ablation of the genicular nerves of the index knee', '7. Prior partial, resurfacing, or total knee arthroplasty of the index knee', '(residual hardware)', '8. Clinically significant ligamentous laxity of the index knee', '9.', 'Clinically significant valgus/varus deformities or evidence of pathology', '(other than osteoarthritis of knee) that materially affects gait or function', 'of the knee or is the underlying cause of the knee pain and/or functional', 'limitations', '10. Body mass index (BMI) > 40 kg/m\u00b2', '11. Extremely thin patients and those with minimal subcutaneous tissue', 'thickness that would not accommodate a radiofrequency lesion of up to', '14 mm in diameter to limit the risk of skin burns', '12. Pending or active compensation claim, litigation, or disability', 'remuneration (secondary gain)', '13. Pregnant, nursing or intent of becoming pregnant during the study', 'period', '14. Chronic pain associated with significant psychosocial dysfunction', 'Version #: 4.0', 'Page 5 of 62', 'Version Date: 28Mar19']\n\n###\n\n", "completion": "END"}